The discovery of novel HDAC3 inhibitors via virtual screening and in vitro bioassay

References

• Saha R, Pahan NK. Hats and hdacs in neurodegeneration: A tale of disconcerted acetylation homeostasis. Cell Death Differ 2005;13:539–50.
   Web of Science ®Google Scholar
• Xia J, Tilahun EL, Kebede EH, et al. Comparative modeling and benchmarking data sets for human histone deacetylases and sirtuin families. J Chem Inf Model 2015;55:374–88.
   PubMed Web of Science ®Google Scholar
• Falkenberg KJ, Johnstone RW. Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders. Nat Rev Drug Discov 2014;13:673–91.
   PubMed Web of Science ®Google Scholar
• Eckschlager T, Plch J, Stiborova M, Hrabeta J. Histone deacetylase inhibitors as anticancer drugs. Int J Mol Sci 2017;18:1414.
   PubMed Web of Science ®Google Scholar
• Pasyukova EG, Vaiserman AM. Hdac inhibitors: a new promising drug class in anti-aging research. Mech Ageing Dev 2017;166:6–15.
   PubMed Web of Science ®Google Scholar
• West AC, Johnstone RW. New and emerging hdac inhibitors for cancer treatment. J Clin Invest 2014;124:30–9.
   PubMed Web of Science ®Google Scholar
• Johnstone RW. Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat Rev Drug Discov 2002;1:287–99.
   PubMed Web of Science ®Google Scholar
• Mahlknecht U, Hoelzer D. Histone acetylation modifiers in the pathogenesis of malignant disease. Mol Med 2000;6:623–44.
   PubMed Web of Science ®Google Scholar
• Minami J, Suzuki R, Mazitschek R, et al. Histone deacetylase 3 as a novel therapeutic target in multiple myeloma. Leukemia 2014;28:680–9.
   PubMed Web of Science ®Google Scholar
• Chen X, Barozzi I, Termanini A, et al. Requirement for the histone deacetylase Hdac3 for the inflammatory gene expression program in macrophages. Proc Natl Acad Sci U S A 2012;109:E2865–74.
   PubMed Web of Science ®Google Scholar
• Leus NG, Zwinderman MR, Dekker FJ. Histone deacetylase 3 (Hdac 3) as emerging drug target in Nf-Kappab-mediated inflammation. Curr Opin Chem Biol 2016;33:160–8.
   PubMed Web of Science ®Google Scholar
• Leus NG, Van Der Wouden PE, Van Den Bosch T, et al. Hdac 3-selective inhibitor Rgfp966 demonstrates anti-inflammatory properties in raw 264.7 macrophages and mouse precision-cut lung slices by attenuating Nf-Kappab P65 transcriptional activity. Biochem Pharmacol 2016;108:58–74.
   PubMed Web of Science ®Google Scholar
• Felice C, Lewis A, Armuzzi A, et al. Review article: selective histone deacetylase isoforms as potential therapeutic targets in inflammatory bowel diseases. Aliment Pharmacol Ther 2015;41:26–38.
   PubMed Web of Science ®Google Scholar
• Mcquown SC, Barrett RM, Matheos DP, et al. Hdac3 is a critical negative regulator of long-term memory formation. J Neurosci 2011;31:764–74.
   PubMed Web of Science ®Google Scholar
• Rogge GA, Singh H, Dang R, Wood MA. Hdac3 is a negative regulator of cocaine-context-associated memory formation. J Neurosci 2013;33:6623–32.
   PubMed Web of Science ®Google Scholar
• Phan ML, Gergues MM, Mahidadia S, et al. Hdac3 inhibitor Rgfp966 modulates neuronal memory for vocal communication signals in a songbird model. Front Syst Neurosci 2017;11:65.
   PubMed Web of Science ®Google Scholar
• Alaghband Y, Kwapis JL, Lopez AJ, et al. Distinct roles for the deacetylase domain of Hdac3 in the hippocampus and medial prefrontal cortex in the formation and extinction of memory. Neurobiol Learn Mem 2017;145:94–104.
   PubMed Web of Science ®Google Scholar
• Jia H, Pallos J, Jacques V, et al. Histone Deacetylase (Hdac) inhibitors targeting Hdac3 and Hdac1 ameliorate polyglutamine-elicited phenotypes in model systems of Huntington's disease. Neurobiol Dis 2012;46:351–61.
   PubMed Web of Science ®Google Scholar
• Jia H, Kast RJ, Steffan JS, Thomas EA. Selective histone deacetylase (Hdac) Inhibition imparts beneficial effects in Huntington’s disease mice: implications for the ubiquitin-proteasomal and autophagy systems. Hum Mol Genet 2012;21:5280–93.
   PubMed Web of Science ®Google Scholar
• Thomas EA. Involvement of Hdac1 and Hdac3 in the pathology of polyglutamine disorders: therapeutic implications for selective Hdac1/Hdac3 inhibitors. Pharmaceuticals (Basel) 2014;7:634–61.
   PubMedGoogle Scholar
• Jia H, Morris CD, Williams RM, et al. Hdac inhibition imparts beneficial transgenerational effects in Huntington's disease mice via altered DNA and histone methylation. Proc Natl Acad Sci U S A 2015;112:E56–64.
   PubMed Web of Science ®Google Scholar
• Jia H, Wang Y, Morris CD, et al. The effects of pharmacological inhibition of histone deacetylase 3 (Hdac3) in huntington’s disease mice. PLoS One 2016;11:e0152498. e0152498
   Web of Science ®Google Scholar
• Christensen D, Dahllof P, Lundh MM, Rasmussen DN, et al. Histone deacetylase (Hdac) inhibition as a novel treatment for diabetes mellitus. Mol Med 2011;17:378–90.
   PubMed Web of Science ®Google Scholar
• SharmaTaliyan SR. Histone deacetylase inhibitors: future therapeutics for insulin resistance and type 2 diabetes. Pharmacol Res 2016;113 (Pt A):320–6.
   Web of Science ®Google Scholar
• Vetere A, Choudhary A, Burns SM, Wagner BK. Targeting the pancreatic beta-cell to treat diabetes. Nat Rev Drug Discov 2014;13:278–89.
   PubMed Web of Science ®Google Scholar
• Larsen L, Tonnesen M, Ronn SG, et al. Inhibition of histone deacetylases prevents cytokine-induced toxicity in beta cells. Diabetologia 2007;50:779–89.
   PubMed Web of Science ®Google Scholar
• Lewis E, Blaabjerg C, Storling LJ, et al. The oral histone deacetylase inhibitor Itf2357 reduces cytokines and protects islet beta cells in vivo and in vitro. Mol Med 2011;17:369–77.
   PubMed Web of Science ®Google Scholar
• Christensen DP, Gysemans C, Lundh M, et al. Lysine deacetylase inhibition prevents diabetes by chromatin-independent immunoregulation and beta-cell protection. Proc Natl Acad Sci U S A 2014;111:1055–9.
   PubMed Web of Science ®Google Scholar
• KhanJena SG. The role of butyrate, a histone deacetylase inhibitor in diabetes mellitus: experimental evidence for therapeutic intervention. Epigenomics 2015;7:669–80.
   PubMed Web of Science ®Google Scholar
• Chou DH, Holson EB, Wagner FF, et al. Inhibition of histone deacetylase 3 protects beta cells from cytokine-induced apoptosis. Chem Biol 2012;19:669–73.
   PubMedGoogle Scholar
• Wagner FF, Lundh M, Kaya T, et al. An isochemogenic set of inhibitors to define the therapeutic potential of histone deacetylases in beta-cell protection. ACS Chem Biol 2016;11:363–74.
   PubMed Web of Science ®Google Scholar
• Lundh M, Galbo T, Poulsen SS, Mandrup-Poulsen T. Histone deacetylase 3 inhibition improves glycaemia and insulin secretion in obese diabetic rats. Diabetes Obes Metab 2015;17:703–7.
   PubMed Web of Science ®Google Scholar
• Dirice E, Ng RWS, Martinez R, et al. Isoform-selective inhibitor of histone deacetylase 3 (Hdac3) limits pancreatic islet infiltration and protects female nonobese diabetic mice from diabetes. J Biol Chem 2017;292:17598–608.
   PubMed Web of Science ®Google Scholar
• Malvaez M, Mcquown SC, Rogge GA, et al. Hdac3-selective inhibitor enhances extinction of cocaine-seeking behavior in a persistent manner. Proc Natl Acad Sci U S A 2013;110:2647–52.
   PubMed Web of Science ®Google Scholar
• Villoutreix BO, Eudes R, Miteva MA. Structure-based virtual ligand screening: recent success stories. Comb Chem High Throughput Screen 2009;12:1000–16.
   PubMed Web of Science ®Google Scholar
• Lionta E, Spyrou G, Vassilatis D, Cournia KZ. Structure-based virtual screening for drug discovery: principles, applications and recent advances. Curr Top Med Chem 2014;14:1923–38.
   PubMed Web of Science ®Google Scholar
• Baig MH, Ahmad K, Roy S, et al. Computer aided drug design: success and limitations. Curr Pharm Des 2016;22:572–81.
   PubMed Web of Science ®Google Scholar
• Xia J, Jin H, Liu Z, et al. An unbiased method to build benchmarking sets for ligand-based virtual screening and its application to Gpcrs. J Chem Inf Model 2014;54:1433–50.
   PubMed Web of Science ®Google Scholar
• Hu H, Xia J, Wang D, et al. A Thoroughly validated virtual screening strategy for discovery of novel Hdac3 inhibitors. Int J Mol Sci 2017;18:137.
   Web of Science ®Google Scholar
• Hsieh JH, Yin S, Wang XS, et al. Cheminformatics meets molecular mechanics: a combined application of knowledge-based pose scoring and physical force field-based hit scoring functions improves the accuracy of structure-based virtual screening. J Chem Inf Model 2012;52:16–28.
   PubMed Web of Science ®Google Scholar
• Xia J, Hsieh JH, Hu H, et al. The development of target-specific pose filter ensembles to boost ligand enrichment for structure-based virtual screening. J Chem Inf Model 2017;57:1414–25.
   PubMed Web of Science ®Google Scholar
• Lipinski C, Lombardo AF, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 2001;46:3–26.
   PubMed Web of Science ®Google Scholar
• Hawkins PC, Skillman AG, Warren GL, et al. Conformer generation with omega: algorithm and validation using high quality structures from the protein databank and Cambridge structural database. J Chem Inf Model 2010;50:572–84.
   PubMed Web of Science ®Google Scholar
• Mcgann MR, Almond HR, Nicholls A, et al. Gaussian docking functions. Biopolymers 2003;68:76–90.
   PubMed Web of Science ®Google Scholar
• Mcgann M. Fred pose prediction and virtual screening accuracy. J Chem Inf Model 2011;51:578–96.
   PubMed Web of Science ®Google Scholar
• Mcgaughey GB, Sheridan RP, Bayly CI, et al. Comparison of topological, shape, and docking methods in virtual screening. J Chem Inf Model 2007;47:1504–19.
   PubMed Web of Science ®Google Scholar
• Zhang S, Golbraikh, Tropsha AA. Development of quantitative structure-binding affinity relationship models based on novel geometrical chemical descriptors of the protein–ligand interfaces. J Med Chem 2006;49:2713–24.
   PubMed Web of Science ®Google Scholar
• Parr RG, Szentpály LV, Liu S. Electrophilicity index. J Am Chem Soc 1999;121:1922–4.
   Web of Science ®Google Scholar
• Shu-Bin L. Conceptual density functional theory and some recent developments. Acta Phys -Chim Sin 2009;25:590–600.
   Web of Science ®Google Scholar
• Chang CC, Lin CJ. Libsvm: a library for support vector machines. ACM T Intel Syst Tec 2011;2:27.21–27:27.
   Web of Science ®Google Scholar
• Villadsen JS, Stephansen HM, Maolanon AR, et al. Total synthesis and full histone deacetylase inhibitory profiling of azumamides a-E as Well as Beta(2)-Epi-azumamide E and Beta(3)-Epi-azumamide E. J Med Chem 2013;56:6512–20.
   PubMed Web of Science ®Google Scholar
• Gaulton A, Bellis LJ, Bento AP, et al. Chembl: a large-scale bioactivity database for drug discovery. Nucleic Acids Res 2012;40:D1100–7.
   PubMed Web of Science ®Google Scholar